Abstracts tagged "Infection"

Abstract Number: 2826 • 2019 ACR/ARP Annual Meeting
Risk of Serious Infections in Tofacitinib versus Other Biologic Drug Initiators in Patients with Rheumatoid Arthritis: A Multi-database Cohort Study
Ajinkya Pawar ¹, Rishi Desai ¹, Nileesa Gautam ¹ and Seoyoung C. Kim², ¹Brigham and Women's hospital, Boston, ²Brigham and Women’s Hospital and Harvard Medical School, Boston
Background/Purpose: It is well-known that biologic or targeted synthetic DMARDs increase the risk of serious infections (SIs), but few studies have directly compared the risk…
Abstract Number: 2873 • 2019 ACR/ARP Annual Meeting
Antimicrobial Use Is High in Patients with Rheumatoid Arthritis, and Further Increases with First-Line TNFi Therapy – Nationwide Results from Iceland
Aron H Bjornsson¹, Olafur Palsson ², Mar Kristjansson ³, Petur S Gunnarsson ⁴, Gerdur Grondal ⁵, Bjorn Gudbjornsson ⁶ and Thorvardur J Love ⁷, ¹Department of Medicine, Landspitali, Reykjavík, Iceland, ²Department of Clinical Sciences Lund, Lund University and Skåne University Hospital, Lund, Sweden, ³Department of Infectious Diseases, Landspitali, Reykjavík, Iceland, ⁴Faculty of Pharmaceutical Sciences, University of Iceland and Hospital Pharmacy, Landspitali, Reykjavík, Iceland, ⁵Department of Rheumatology, Landspitali and Centre for Rheumatology Research, Landspitali, Reykjavík, Iceland, ⁶Centre for Rheumatology Research, Landspitali and Faculty of Medicine, University of Iceland, Reykjavik, Iceland, ⁷Faculty of Medicine, University of Iceland and Department of Science, Landspitali, Reykjavík, Iceland
Background/Purpose: Severe infections, frequently resulting in hospitalization, are a well-known adverse effects of tumor necrosis factor inhibitors (TNFi). However, studies regarding outpatient treated infections are…
Abstract Number: 848 • 2019 ACR/ARP Annual Meeting
Risk of Serious Infection with Long-Term Use of Low-Dose Glucocorticoids in Patients with Rheumatoid Arthritis
Michael George¹, Joshua Baker ², Kevin Winthrop ³, Qufei Wu ², Lang Chen ⁴, Fenglong Xie ⁵, Huifeng Yun ⁴ and Jeffrey Curtis ⁴, ¹University of Pennsylvania, Philadelphia, ²University of Pennsylvania, Philadelphia, PA, ³Oregon Health and Science University, Portland, OR, ⁴University of Alabama at Birmingham, Birmingham, AL, ⁵University of Alabama at Birmingham, Birmingham
Background/Purpose: As many as 30-40% of patients with RA remain on long term glucocorticoids. Infection risk with higher dose glucocorticoids is well known, but evidence…
Abstract Number: 951 • 2019 ACR/ARP Annual Meeting
Avoidable Acute Care Use for Vaccine-Preventable Illnesses Among Medicaid Beneficiaries with Lupus: Demographic and Healthcare Utilization Differences
Candace Feldman¹, Chang Xu ¹ and Karen Costenbader ¹, ¹Brigham and Women's Hospital, Boston, MA
Background/Purpose: Nearly 25% of patients with SLE are hospitalized each year often for outcomes that may have been avoided if patients had received sustained, high…
Abstract Number: 1374 • 2019 ACR/ARP Annual Meeting
Real-World Evidence: Infections Among RA Patients Switching from First Biologic DMARD to Another Treatment in the US
Robin Dore¹, Jenya Antonova ², Huan Huang ³, Lawrence Chang ², Xin Wang ³ and Mark Genovese ⁴, ¹Private practice, Tustin, CA, ²Gilead Sciences, Foster City, CA, ³IQVIA, Plymouth Meeting, PA, ⁴Stanford University, Stanford, CA
Background/Purpose: Infections are common safety events monitored in RA patients.1 ACR guidelines limit the use of live vaccines in patients who are on biologic (b)DMARDs…
Abstract Number: 1515 • 2019 ACR/ARP Annual Meeting
Infections in Patients with Active Radiographic Axial Spondyloarthritis Treated with Ixekizumab in 2 Phase 3 Clinical Trials
Marina Magrey¹, Victoria Navarro-Compán ², Sandra Garces ³, Xenofon Baraliakos ⁴, David Sandoval ³, Jeffrey Lisse ³, Silvia Santisteban ³, David Adams ³, Fangyi Zhao ³ and Robert Inman ⁵, ¹Division of Rheumatology, The MetroHealth System and School of Medicine, Case Western Reserve University, Cleveland, OH, ²University Hospital La Paz, IdiPaz, Madrid, Spain, ³Eli Lilly and Company, Indianapolis, IN, ⁴Rheumazentrum Ruhrgebiet-Ruhr-University Bochum, Herne, Germany, Herne, Germany, ⁵University of Toronto, University Health Network, Toronto, ON, Canada
Background/Purpose: Ixekizumab (IXE) is a high-affinity monoclonal antibody that selectively targets IL-17A. IL-17 inhibitors have shown efficacy for radiographic axial spondyloarthritis (r-axSpA), with IXE currently…
Abstract Number: 1805 • 2019 ACR/ARP Annual Meeting
Perioperative Anti-rheumatic Medications Are Not Associated with 30-day Odds of Infection in Rheumatoid Arthritis Patients Undergoing Surgery: A Retrospective Cohort Study
Marianne Kerski¹, Peter Boersma ², Eric Miller ³, Ashley Brenner ⁴, Genevieve Melton ⁵ and Anna Shmagel ⁶, ¹University of Minnesota Medical School, Minneapolis, MN, ²University of Minnesota School of Public Health, Minneapolis, ³University of Minnesota, Woodbury, MN, ⁴University of Minnesota Best Practices Integrated Informatics Core (BPIC), Minneapolis, MN, ⁵University of Minnesota Department of Surgery, Minneapolis, MN, ⁶University of Minnesota, Minneapolis, MN
Background/Purpose: Perioperative management of anti-rheumatic drugs in rheumatoid arthritis (RA) patients undergoing surgery remains controversial. Previous studies produced conflicting results, and data on non-orthopedic surgeries…
Abstract Number: 2095 • 2019 ACR/ARP Annual Meeting
A Quality Improvement Intervention to Improve Influenza and Pneumococcal Vaccination Rates in Immunosuppressed Inflammatory Arthritis Outpatients
Kieran Murray¹, Candice Low ¹, Francis Young ¹, Anna O'Rourke ¹, Ian Callanan ², Eoin Feeney ¹ and Douglas Veale ³, ¹Saint Vincent's University Hospital, Dublin, Ireland, ²Saint Vincent's University Hospital, Dublin, Dublin, Ireland, ³EULAR Centre For Arthritis And Rheumatic Diseases and The Conway Institute, Dublin, Ireland
Background/Purpose: The ACR and CDC recommend influenza (“flu”) and 23-valent pneumococcal polysaccharide (PPSV23) vaccination for inflammatory arthritis (IA) patients on immunosuppression. This study aimed to:…
Abstract Number: 745 • 2018 ACR/ARHP Annual Meeting
Prolonged Remission and Influence on Damage Accrual and Infection for Patients with Systemic Lupus Erythematosus: A Multi-Center Cohort Study from China
Ziqian Wang¹, Jiuliang ZHAO², Yanhong Wang³, Mengtao Li⁴ and Xiaofeng Zeng⁵, ¹Peking Union Medical College Hospital, China, Beijing, China, ²Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Beijing, China, ³Department of Epidemiology and Bio-statistics (YW), Academy of Medical Sciences & Peking Union Medical College, Beijing, China, ⁴Department of Rheumatology, Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, China, ⁵Rheumatology, Peking Union Medical College and Chinese Academy of Medical Sciences, Peking Union Medical College Hospital, Beijing, China
Prolonged Remission and Influence on Damage Accrual and Infection for Patients with Systemic Lupus Erythematosus: a Multi-center Cohort Study from ChinaZiqian Wang1, Jiuliang Zhao1, Yanhong…
Abstract Number: 1611 • 2018 ACR/ARHP Annual Meeting
Hospitalizations for Serious Infections in Psoriatic Arthritis Patients: Data from the National Inpatient Sample 2000-2014
Paras Karmacharya¹, Cynthia S. Crowson², Dilli Poudel³, Pragya Shrestha⁴ and Kerry Wright⁵, ¹Division of Rheumatology, Mayo Clinic, Rochester, MN, ²Health Sciences Research, Mayo Clinic College of Medicine and Science, Rochester, MN, ³Internal Medicine, Reading Hospital-Tower Health System, WEST READING, PA, ⁴Internal medicine, Reading Hospital-Tower Health System, West Reading, PA, ⁵Rheumatology, Mayo Clinic, Rochester, MN
Background/Purpose: Increased risk of infections has been recognized in patients with psoriatic arthritis (PsA) compared to those without PsA. Immunomodulatory effects of PsA, immunosuppressive therapies…
Abstract Number: 769 • 2018 ACR/ARHP Annual Meeting
Herpes Zoster in Systemic Lupus Erythematosus: Prevalence and Risk Factors
Hanan Al Rayes¹, Nicole Anderson², Dennisse Bonilla², Jiandong Su² and Zahi Touma², ¹Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Herpes zoster (HZ) commonly observed in the elderly and in immune-compromised patients. The prevalence of HZ is 3.6-19.9% in previously reported data. The higher…
Abstract Number: 1883 • 2018 ACR/ARHP Annual Meeting
Infections Are Associated With Increased Risk of Giant Cell Arteritis – a Population-Based Case-Control Study From Southern Sweden
Pavlos Stamatis¹, Aleksandra Turkiewicz², Martin Englund², Goran Jönsson³, Jan-Åke Nilsson⁴, Carl Turesson⁵ and Aladdin Mohammad⁶, ¹Clinical Sciences, Rheumatology Lund, Lund University, Lund, Sweden, ²Clinical Sciences Lund, Clinical Epidemiology Unit, Lund University, Lund, Sweden, ³Clinical Sciences Lund, Department of Infection Medicine, Lund University, Lund, Sweden, ⁴Department of Rheumatology, Skåne University Hospital, Malmö, Sweden, ⁵Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden, ⁶Rheumatology, Department of Clinical Sciences, Lund, Lund University, Lund, Sweden
Background/Purpose: Previous studies have implicated infections as a risk factor for giant cell arteritis (GCA). The purpose of this study was to investigate the association…
Abstract Number: 772 • 2018 ACR/ARHP Annual Meeting
Cytomegaloviral or Pneumocystis Jiroveci Pneumonia Increases Mortality Rate in Systemic Lupus Erythematosus Patients with Pulmonary Hemorrhage: Evidence from Bronchoalveolar Lavage Fluid Analysis
Chien-Chih Lai, Yi-Syuan Sun and De-Feng Huang, Allergy, Immunology, Rheumatology, Taipei Veterans General Hospital, Taiwan, Taipei City, Taiwan
Background/Purpose: To evaluate the role of cytomegaloviral or Pneumocystic jiroveci pneumonia (CMV/PJP) in SLE patients with pulmonary hemorrhage (PH).Methods: We retrospectively examined hospital records for…
Abstract Number: 2142 • 2018 ACR/ARHP Annual Meeting
Exposure to Disease Modifying Antirheumatic Drugs during Pregnancy in Women with Inflammatory Arthritis and the Risk of Serious Maternal Infection: A Population-Based Cohort Study
Mary A. De Vera^1,2,3, Nicole W. Tsao^1,2,3, Eric C. Sayre² and Alyssa Howren^1,2,3, ¹Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada, ²Arthritis Research Canada, Richmond, BC, Canada, ³Collaboration for Outcomes Research and Evaluation (CORE), Vancouver, BC, Canada
Background/Purpose: Infection risk is one of the concerns regarding therapy with conventional disease modifying antirheumatic drugs (csDMARDs) and to our knowledge no research has examined…
Abstract Number: 784 • 2018 ACR/ARHP Annual Meeting
Prediction of Hospital-Acquired Bacterial Infections in Patients with SLE
Pablo Castaño-Gonzalez¹, Mauricio Restrepo-Escobar^1,2, Laura Morales-Maya¹, Tomás Urrego¹, Simon Sandoval-Alvares¹, Carlos Horacio Muñoz^1,3, Adriana L Vanegas^1,3, Daniel Jaramillo^1,4, Gloria Vasquez¹ and Luis Gonzalez-Naranjo¹, ¹Division of Rheumatology, Department of Internal Medicine, School of Medicine, Universidad de Antioquia, Medellin, Colombia, ²Hospital Universitario Pablo Tobon Uribe, Medellin, Colombia, ³Hospital Universitario de San Vicente Fundación, Medellín, Colombia, ⁴Hospital Universitario de San Vicente Fundación, Medellin, Colombia
Background/Purpose: Patients with SLE have an increased risk of serious infections, including nosocomial infections, which are associated with potentially modifiable adverse outcomes. Our objective is…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].